Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial

NCT00754624 · View on ClinicalTrials.gov ↗

Study Summary

Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005

Conditions Studied

Interventions

  • DRUG Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler

Study Locations (20)

Texas

  • Dallas Diabetes & Endocrine Center — Dallas
  • University of Texas Southwestern Medical Center — Dallas
  • Texas Diabetes Institute — San Antonio
  • Diabetes & Glandular Disease Research Assoc PA — San Antonio

Connecticut

  • Alliance Medical Group of Greater Waterbury — Middlebury
  • The Hospital of Central Connecticut — New Britain
  • Soundview Research Associates — Norwalk

BGR

  • MBAL "Pleven" — Pleven
  • SBALENG-Sofia Institute of Endocrinology — Sofia
  • MBAL Alexandrovska Hospital — Sofia

California

  • Dorothy L & James E Frank Diabetes Research Institute — San Mateo
  • Sansum Medical Research Institute — Santa Barbara

New York

  • Diabetes Care & Information Center of New York — Flushing
  • Diabetes Team Associated — New York

Florida

  • University of Miami School of Medicine — Miami

Louisiana

  • Oschner Clinic Foundation — New Orleans

Minnesota

  • International Diabetes Center — Minneapolis

Trial Details

FieldValue
Enrollment Target 229 participants
Start Date 2004-05
Est. Completion 2008-10
Phase Phase 2

Sponsor

Mannkind Corporation

39 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00754624

The ClinicalTrials.gov registry entry for NCT00754624 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 39 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention — of which Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00754624 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Texas, Connecticut, BGR. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00754624 about?

NCT00754624 is a clinical study titled "An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial". Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005

What is the current status of trial NCT00754624?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2004-05. Estimated completion is 2008-10.

What conditions does trial NCT00754624 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00754624?

The interventions under investigation include: Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00754624?

This trial is sponsored by Mannkind Corporation, which has 39 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00754624 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial